Our Story

HeartFlow is a medical technology company revolutionizing precision heart care.

There is no company in the world doing what we do—combining decades of human ingenuity and advanced technology in a completely novel way. We are passionate about transforming the diagnosis and management of coronary artery disease and continue to innovate, pushing into new frontiers and forging incredible partnerships along the way. Learn more about our story below.

The HeartFlow Story

Hear from our founders and customers around the world who are using our innovative technology as they tell the HeartFlow story and describe what makes our company and technology so transformational.

HeartFlow Virtual Tour & Product Overview

Take a virtual tour with leaders from our organization as they explain step-by-step how the HeartFlow technology works, the problem it is solving and how HeartFlow continues to innovate.

The HeartFlow Difference

Physicians and patients agree that the HeartFlow Analysis is a revolutionary technology that is dramatically improving the care for patients with coronary artery disease. Hear their stories below.

Our History

  • 1995

    Began development of image-based modeling for coronary blood flow

    Charles Taylor PhD: expert in computational fluid dynamics at Stanford University

    Christopher Zarins MD: chair of vascular surgery at Stanford University

  • 2010

    Founded HeartFlow in Silicon Valley, California

  • 2011

    Awarded CE Mark

    Commercially available in Europe

  • 2014

    Received U.S. FDA de novo 510(k) clearance

    Commercially available in the U.S.

  • 2015

    Commercially available in Canada

    Launched ADVANCE Registry to evaluate data from 5,000 patients

  • 2016

    Commercially available in Japan

    > 150 peer-reviewed publications
    > 150 issued and allowed patents worldwide

  • 2017

    NICE Guidance recommends HeartFlow

    > 10,000 patients worldwide have received the HeartFlow Analysis

    Announced collaboration with Siemens Healthineers

  • 2018

    Innovation and Technology Payment Program Awarded by NHS England

    Received reimbursement approval in Japan from MHLW

    Launched PRECISE Randomized Clinical Trial

  • 2019

    Named one of the World’s Most Innovative Companies by Fast Company

    FDA Clearance Received for HeartFlow Planner

  • 2020

    FORECAST trial results show increased treatment efficiency with HeartFlow Analysis

    JAMA Network Open Publication Demonstrates the Coronary CT-HeartFlow Analysis Pathway is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis

  • 2021

    NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease

    Completes Patient Enrollment in the PRECISE Trial

While we continue to trailblaze in the field of cardiology, we are proud of our numerous accomplishments bringing us to where we are today, including more than 170,000 patients served, adoption at more than 400+ hospitals worldwide—including 80% of the Top 50 US Heart Hospitals—full coverage by Medicare and 96% of commercial lives in the United States, a robust body of clinical evidence including more than 500 peer-reviewed publications, and an IP portfolio of more than 400 issued and allowed patents worldwide. We are committed to continuing to transform the diagnosis and management of coronary artery disease and are grateful for the countless collaborations today and in the future to make this vision a reality worldwide.

125675228 v1